Polatuzumab vedotin (Polivy) targets CD79b on B-cell tumors and was approved in 2019 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with chemotherapy. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.